Other Events ·
Annovis Bio reports preliminary cash and cash equivalents of $2.8 million as of September 30, 2026
ANVSAnnovis Bio, Inc.
Annovis Bio provided preliminary estimates indicating that its cash and cash equivalents stood at approximately $2.8 million as of September 30, 2026. The company noted that interim financial statements for the three and nine months ended on that date are not yet available and the quarterly closing process is incomplete. These figures are unaudited, subject to change, and should not be viewed as a substitute for full GAAP financial statements. Annovis Bio operates in the biotechnology sector, focusing on the development of therapies for rare genetic diseases.